You are here:

fondaparinux (Arixtra)

Advice

Following a full submission

fondaparinux (Arixtra®) is accepted for use within NHS Scotland for the treatment of unstable angina or non-ST segment elevation myocardial infarction in patients for whom urgent (<120minutes) invasive management (Percutaneous Coronary Intervention) is not indicated.

Fondaparinux was shown to be non-inferior to a low molecular weight heparin in preventing death, myocardial infarction or refractory ischaemia in the nine days following onset of symptoms. Fondaparinux also had a significantly lower major bleeding event rate than a low molecular weight heparin.

Drug Details

Drug Name: fondaparinux (Arixtra)
SMC Drug ID: 420/07
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 December 2007

Back